Immunome, Inc.
NASDAQ:IMNM
9.4 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | Immunome, Inc. |
| Symbool | IMNM |
| Munteenheid | USD |
| Prijs | 9.4 |
| Beurswaarde | 818,223,000 |
| Dividendpercentage | 0% |
| 52-weken bereik | 5.15 - 16.73 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Clay B. Siegall Ph.D. |
| Website | https://immunome.com |
An error occurred while fetching data.
Over Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)





